Kornimate/medical-research-clean huggingface dataset:
a retrospective study to evaluate neurostar® advanced therapy in adolescents

Conditions: MDD

Summary: to assess the real-world effectiveness of transcranial magnetic stimulation (tms) for depression in large adolescent and young adult samples.

this is a retrospective analysis. the purpose of this study is to collate real world data (rwd) from existing medical records of patients aged 12 to 21 years who received treatment with neurostar advanced therapy for major depressive disorder (mdd) as determined by scores on the phq-9 and cgi-s assessment tool into a central registry database.

Eligibility criteria:
inclusion criteria: 1. primary diagnosis of major depressive disorder (mdd), according to dsm-4/icd-9 or dsm-5/icd-10 criteria applicable on the date treatment with neurostar advanced therapy begins. 2. 12 to 21 years of age. 3. male or female. 4. treatment with neurostar advanced therapy. 5. treatment start-date of november 1, 2008, or later. 6. treatment end date on or before the date on which the retrospective study sample is extracted from the trakstar database. 7. a) per protocol subjects: subject received a course of a minimum of 20 treatments with neurostar advanced therapy. b) intent-to-treat (itt) subjects: subject received at least one treatment with neurostar advanced therapy. 8. treatment with neurostar advanced therapy to the left dorsolateral prefrontal cortex (dlpfc) only. 9. treatment with neurostar advanced therapy according to standardized neurostar advanced therapy treatment protocols of dash and/or standard per the current fda clearance. 10. each of gad-7 and phq-9 scores available at each of pre-treatment (defined as the closest score available within 7 days prior to administration of the first treatment) and post-treatment (defined as the closest score available within ± 7 days of the date of the last treatment) evaluations for the single neurostar advanced therapy course. 11. subjects with moderate or greater depression prior to neurostar advanced therapy (pre-treatment), defined as a score on the physician health questionnaire-9 (phq-9) ≥ 10 within 7 days prior to the first treatment. exclusion criteria: - 1. gap in neurostar advanced therapy treatment \> 14 continuous days, where applicable. 2. more than one dlpfc treatment session on the same day.
long-term cpap effect with obstructive sleep apnea: a telemedicine-based

Conditions: Obstructive Sleep Apnea

Summary: we hypothesize that long-term cpap could results in increase weight and muscle composite by changing intake content and hormone and the effect was influenced by presence of cvd, social jet lag, and cpap compliance. the project aims to conduct a telemedicine-based, multicenter, rcts to compare the effect of 48-week cpap and usual care on social jet lag, muscular fat, hormone, and attention and memory in 100 participants with moderate-severe osa.

after the participants enter the trial, participants underwent two-night home psg to confirm the diagnosis of osa. once ahi ³15/h is confirmed, participants undertake baseline evaluation within two weeks which included standard questionnaire, eating behavior, 3-day photograph-based intake recording, and 7-day sleep log, 24-hr ambulatory blood pressure, 7-day actiwatch and actigraph, 2-morning attention and memory task at home environment. the bmr, bc, proton magnetic resonance spectroscopy (1h-mrs), and blood sampling are conducted in the morning when patients was fasting at hospital. once participants complete the baseline evaluation, they are randomly allocated to the usual care or auto-cpap treatment (airsense™ 10 autoset™, resmed inc., australia) for 48 weeks. the randomization is generated by the staff of the department of biostatistics independent of subject enrolment. a block-randomized assignment with a block size of four is used. consecutive patients are assigned to the allocation according to the randomization schedule by the study nurse. after randomization, participants had virtual visits at 4th, 12th, 24th, and 48th week and are evaluated with the same measurements as pre-randomization after complete the trial. once the patients complete the trial, they receive the standard treatment of osa and are followed every 24 to 48 weeks for five years.

Eligibility criteria:
inclusion criteria: 1. age:≧20 year-old 2. patients with moderate-severe osa (ahi≥15/hr) exclusion criteria: 1. skin allergy 2. wrist tattoos 3. bmi≧40 kg/m2 4. neurological disorders(infection, stroke, als, myopathy, brain tumor and encephalitis) 5. internal diseases(cardiovascular disease or coronary artery disease was poorly controlled 6. chronic heart failure(including nyha class 3 or more than nyha class 3) 7. copd(fev1/fvc\<70) 8. hyperthyroidism or hypothyroidism 9. primary aldosteronism 10. chronic kidney disease(egfr\<30) 11. acromegaly and parkinson's disease) 12. psychosis(schizophrenia, bipolar disorder and depression) 13. autoimmune disease(system lupus erythematosus, rheumatoid arthritis, sarcoidosis, crohn's disease and ulcerative colitis) 14. cancer(in last 5 years) 15. have been diagnosed with obstructive sleep apnea 16. other sleep disorder(narcolepsy, insomnia and rbd) 17. use anti-inflammatory drugs(in last 2 weeks) 18. illiterate 19. shift worker 20. has been spinal surgery and move difficult 21. professional driver has severe drowsiness

Keywords: body composition continuous positive airway pressure obstructive sleep apnea social jet lag cognition muscular lipid
effects of vitamin d supplementation in obesity

Conditions: Vitamin D Deficiency; Obesity

Summary: obesity is an increasing health problem with numerous metabolic complications. vitamin d deficiency is common in obesity, and in epidemiological studies vitamin d deficiency has been linked to metabolic complications, such as type 2 diabetes, insulin resistance and cardiovascular disease, as well as myopathy, osteoporosis and depression. in obesity, a low grade inflammation is present in the fat tissue, thereby releasing inflammatory molecules to the blood stream. in cell line studies as well as small clinical studies vitamin d has been shown to have the ability to reduce inflammation and cell growth. in the present study the investigators wish to investigate the effect of vitamin d on fat-, muscle and bone metabolism. 30 healthy obese subjects will be treated with cholecalciferol 175 micrograms daily for 6 months and will be compared with 30 healthy obese subjects treated with placebo. the investigators hypothesize that restoring vitamin d levels in vitamin d deficient obese subject will reduce inflammation and thereby reduce obesity-related complications. the effect will be evaluated as follows: * levels of circulating inflammatory markers will be examined in blood samples collected prior to and after treatment. * effects on fat- and muscle metabolism will be evaluated in fat- and muscle samples taken before and after treatment. * effects on fat distribution will be evaluated by mri scan before and after treatment. * effects on insulin sensitivity will be evaluated by hyperinsulinaemic euglycaemic clamp performed on a subgroup of subjects with impaired fasting glucose. * effects on bone marrow density will be evaluated by dexa scans before and after treatment. * effects on quality of life and depression score will be evaluated by questionnaires used before and after treatment.


Eligibility criteria:
inclusion criteria: * healthy obese (bmi 30 - 45 kg/m2) * 25(oh) vitamin d \< 50 nmol/l exclusion criteria: * diabetes, * pregnancy or non-safe contraception, * vitamin d treatment within 3 months, * hypercalcaemia, renal failure, * liver failure, non eligibility for mri-scan, * severe osteomalacia, * allergy towards study drug
wear your mask, wash your hands, don't get covid-19

Conditions: Coronavirus; Child, Only

Summary: the aim of this project is to determine the effect of training given to children aged 11-14 on hand hygiene and mask use. in line with this general purpose, the hypotheses of the research are as follows: h0= education given to children aged 11-14 on hand hygiene and mask use has no effect on children's hand hygiene and mask use behaviors. h1= with the education given to children aged 11-14 on hand hygiene and mask use, children will exhibit more correct hand hygiene and mask use behaviors.

the universe of the research will consist of 273 secondary school students between the ages of 11-14 according to the education and training of bartın ertuğrul gazi secondary school. the children's inclusion criteria are as follows: * being between the ages of 11-14, * being a student of bartın ertuğrul gazi secondary school, * the child and his parents agree to participate in the project, * the child's speech and visual impairment do not have any handicap that would force or hinder communication. intervention: once enrolled and consent is documented, eligible subjects will participate in the study for approximately three months. participants will be expected to attend 2 training sessions and 2 activities (wearing masks and hygienic hand washing), each is up to one hour in length. follow-up will be made at the beginning of the training, right after the last training. data analysis will begin once all trainings and activities have been completed. investigators anticipate completing the study, including primary analyses, within six months from the date recruitment begins.

Eligibility criteria:
inclusion criteria: * being between the ages of 11-14, * being a student of bartın ertuğrul gazi secondary school, * the child and his parents agree to participate in the project, * the child's speech and visual impairment do not have any handicap that would force or hinder communication. exclusion criteria: * not to be between the ages of 11-14, * not being a student of bartın ertuğrul gazi secondary school, * the child and his parents do not agree to participate in the project, * the child's speech and vision impairment, or any disability that would force or hinder communication.
evaluation of a diagnostic to identify glucose-6-phosphate dehydrogenase (g6pd) deficiency in brazil

Conditions: G6PD Deficiency

Summary: th objectives of this study are: * to determine the performance of g6pd tests in detecting g6pd activity and hemoglobin (hb) compared to a reference assay * to assess the comprehension of the g6pd test packaging and labelling among intended users * to assess the usability of g6pd test result outputs among intended users

this is a cross-sectional diagnostic accuracy study that includes both participants and health worker participants. the participant population will be recruited at clinics and through a household survey using an enriched sample of a population with known g6pd status, established through previous epidemiological studies. clinic staff will take capillary blood samples and conduct two point of care (poc) tests: 1) hemocue® hemoglobin test, and 2) the investigational standard diagnostics (sd) biosensor standard poc test for glucose-6-phosphate dehydrogenase (g6pd) deficiency. venous blood will be collected and transferred to a laboratory where reference assays will be performed on venous samples using the pointe scientific g6pd analyzer and hemoglobin tests. the health worker participants will include trained intended users of the g6pd tests. trained health workers will be surveyed to assess product usability through a questionnaire to assess label and packing comprehension as well as results interpretation.

Eligibility criteria:
1. participants with unknown g6pd status inclusion criteria: * febrile patients seeking care at the manaus or porto velho clinics * 2 years age or older * willing to provide informed consent exclusion criteria * younger than 2 years of age * participants who received a blood transfusion in the last 3 months, self report * unwilling to provide informed consent 2. participants with known g6pd status inclusion criteria: * included in previous g6pd surveys and provided consent to be contacted again * 2 years of age or older * willing to provide informed consent or assent exclusion criteria: * younger than 2 years of age * participants who received a blood transfusion in the last 3 months, self report * unwilling to provide informed consent or assent or unavailable during study visit 3. health workers inclusion criteria: * provides malaria case management at study facility or study site * considered an intended user of quantitative poc g6pd tests * trained and proficient in the use of the poc g6pd test * willing to provide informed consent exclusion criteria: * does not provide malaria case management at study facility or study site * not considered an intended user of quantitative poc g6pd tests * not trained or not proficient in the use of the poc g6pd test * unwilling to provide informed consent

Keywords: g6pd deficiency
budapest upgrade crt study (version 009-4.1)

Conditions: Cardiomyopathy

Summary: effect of biventricular upgrade on left ventricular reverse remodeling and clinical outcomes in patient in left ventricular dysfunction and intermittent or permanent apical/septal right ventricular pacing (budapest crt upgrade study)

the aim of this study is to investigate the effect of upgrade to a crt-d device on clinical and echocardiographic response at 12-month in patients with left ventricular dysfunction (lvef ≤35%), symptomatic heart failure (nyha ii, iii, iv-a), and intermittent or permanent right ventricular pacing with paced qrs complex ≥ 150 ms compared to continued therapy with a single or dual chamber pacemaker (pm) or icd. prospective, post-market, international multicenter randomized controlled trial.

Eligibility criteria:
inclusion criteria: * male or female patients over the age of 18 (expected survival time: over 1 year) * patients with ischemic or non-ischemic cardiomyopathy; * those implanted with a single or dual chamber icd or implanted with a single or dual chamber pacemaker at least 6 months before inclusion; * elective generator replacement or upgrade from pacemaker-only to icd therapy may be indicated at the time of enrollment, but are not required; * right ventricular pacing 20-100% in at least the last 90 days before enrollment (with an optimal av interval based on the physician's discretion to avoid unnecessary right ventricular stimulation); * symptomatic heart failure for at least 3 months before inclusion; * nyha functional class ii or iii, or iv a; * left ventricular ejection fraction measured by echocardiography ≤ 35%; * paced qrs complex ≥ 150 ms; * optimal heart failure medical therapy; * informed consent obtained. exclusion criteria: * intrinsic qrs with lbbb morphology (measured at vvi 40 bpm setting as per protocol); * cabg or pci in the past 3 months; * acute myocardial infarction in the past 3 months; * unstable angina; * planned coronary revascularization (pci or cabg); * planned cardiac transplantation; * acute myocarditis; * infiltrative myocardial disease; * hypertrophic cardiomyopathy; * severe primary mitral and aortic valve stenosis or regurgitation; * women who are pregnant or plan to become pregnant or breastfeeding; * subjects who are unable or unwilling to cooperate with the study protocol; * tricuspid valve prosthesis; * any serious disease likely to interfere with the conduct of the study; * participation in other clinical trial; * patients geographically not stable or unavailable for follow-up; * chronic, severe renal dysfunction (creatinine value \> 200 μmol/l); * severe rv dilatation (rv basal diameter \>50mm); * severe tricuspid insufficiency.

Keywords: cardiac resynchronization therapy
a registry of peripartum cardiomyopathy in turkey

Conditions: Peripartum Cardiomyopathy

Summary: peripartum cardiomyopathy (ppcm) is a global disease with significant morbidity and mortality of young women. its' etiology, epidemiology and treatment is not yet well described. this will be a retrospective, national, multicenter observational study, conducted in turkey. it is expected that approximately 50 women with ppcm will be recorded.

peripartum cardiomyopathy (ppcm) is a global disease with significant morbidity and mortality of young women. its' etiology, epidemiology and treatment is not yet well described. this will be a retrospective, national, multicenter observational study, conducted in centres in turkey. it is expected that approximately 50 women with ppcm will be recorded. the objectives of the study are: to define the clinical status and clinical characteristics of ppcm in turkey to define the outcome of ppcm (short and long term) to define the demographical and possible etiological factors to define prognostic factors

Eligibility criteria:
inclusion criteria: * patient above 18 years of age * unexplained heart failure symptoms developed towards the end of pregnancy or in the first 6 months of postpartum period * ejection fraction less than 45% documented with echocardiography exclusion criteria: * patients with any other known cardiac pathology

Keywords: peripartum cardiomyopathy heart failure
banding versus propranolol for primary prophylaxis of variceal bleeding

Conditions: Liver Cirrhosis; Esophageal Varices

Summary: whether beta-blockers or banding is the best therapy for primary prophylaxis of variceal bleeding is subject to debate. a randomized comparison between the two treatments was performed in candidates for liver transplantation. patients with child b and c cirrhosis with high risk varices and no previous variceal bleeding are randomized to propranolol or variceal bleeding. primary end point is variceal bleeding


Eligibility criteria:
inclusion criteria: * liver cirrhosis * child pugh\>=b7 * studied for transplantation * age between 18 an 65 ys * no previous bleeding from varices * signed informed consent exclusion criteria: * esophageal varices less than f2 blue * gastric varices * previous variceal surgical or radiological or endoscopical treatment * hepatocarcinoma * portal vein thrombosis * severe heart, respiratory or renal failure * contraindications to betablockers * treatment with nitrates, calcium antagonist or anti-arhythmic drugs that can not be suspended * pregnancy * neoplasias * non cooperation
acceptability and tolerance study of a high energy peptide based paediatric oral nutritional supplement for children

Conditions: Nutrition Disorder, Child

Summary: this is an acceptability study (including gastrointestinal tolerance, compliance and palatability) of a high energy peptide based paediatric oral nutritional supplement for children over 12 months of age. the acceptability data from a minimum of 15 participants will be collected in order to submit an application to the advisory committee on borderline substances (acbs).

fifteen (15) participants, aged 12 months and over, requiring a high energy peptide based oral nutritional supplement drink for the dietary management. the acbs requirement for evaluable data on 15 participants has informed the trial's recruitment target; however, we may need to exceed this target if any patients give their consent to join the study but then decide not to participate in the study. participants who join the study and begin using the product would count towards the recruitment total and their data would be included in a submission to the acbs whether they complete the 7-day study period or not. each potential participant must meet all of the inclusion criteria and not meet any of the exclusion criteria.

Eligibility criteria:
inclusion criteria: i. children aged 1 year and over who require 1-3 bottles of an oral nutritional peptide based supplement drink ii. children who require an oral nutritional supplement or who are already established on a nutritional supplement drink iii. children who require a nutritional supplement drink as bolus feeding via a feeding tube. iv. children being able to communicate views of acceptability v. willingly given, written, informed consent from patient or parent/guardian. vi. willingly given, written assent (if appropriate). exclusion criteria: i. inability to comply with the study protocol, in the opinion of the investigator. ii. contraindications to any feed ingredients (see nutritional table and ingredients list) iii. require a milk free diet iv. children under the age of 12 months v. emergencies
efficacy of selective laser trabeculoplasty in patients under treatment with topical prostaglandines

Conditions: Glaucoma; Ocular Hypertension

Summary: retrospective analysis of efficacy of selective laser trabeculoplasty in patients under treatment with topical prostaglandins compared to patients without topical prostaglandins is performed. inclusion criterion are patients with glaucoma or ocular hypertension, who underwent treatment with selective laser trabeculoplasty due to insufficient control of intraocular pressure during their routine treatment at the university hospital zurich / division of ophthalmology.


Eligibility criteria:
inclusion criteria: * patients with ocular hypertension or glaucoma who underwent selective laser trabeculoplasty due to insufficient control of intraocular pressure despite maximum tolerated topical treatment. exclusion criteria: * optic neuropathy other than glaucoma

Keywords: glaucoma and ocular hypertension
tailored ovarian stimulation based on bmi, amh, afc

Conditions: Infertility

Summary: the study objective is to develop a tailored based strategy for ovarian stimulation in ivf patients using amh, bmi, antral follicle count (afc). 300 patients will be randomized in 2 arms: 1. control group: standard care rec fsh. 2. study group: modified dose of rec fsh based on afc with a correction factor based on bmi and basal amh level. primary endpoints: number of mature follicles and eggs collected at egg retrieval; amount of rec fsh used. secondary endpoints: fertilization rate; cleavage rate; clinical pregnancy rate; inhibin b and amh levels during ovarian stimulation.

the study objective is to develop a tailored based strategy for ovarian stimulation in ivf patients using amh, bmi, afc and inhibin b. 300 patients will be stimulated with rec fsh and an antagonist pituitary inhibition protocol, and randomized (at random computer generated numbers) in 2 arms: 1. control group: standard care recfsh based on age, basal fsh and afc. 2. study group: modified dose of rec fsh based on afc with a correction factor based on bmi and basal amh level. fsh administration: 20iu per antral follicle (from 2-5mm) corrected as follows: correction factor for amh: \ 18 pmol/l x0.5 bmi 16.5-18.5 x0.75 18.5-25 x1 25-30 x1.25 30-35 x1.5 35-40 x2 primary endpoints: number of mature follicles and eggs collected at egg retrieval; amount of rec fsh used. secondary endpoints: fertilization rate; cleavage rate; clinical pregnancy rate; inhibin b and amh levels during ovarian stimulation.

Eligibility criteria:
inclusion criteria: * female infertile patients eligible for ivf treatment exclusion criteria: * polycystic ovaries * untreated thyroid pathology * hypogonadotropic hypogonadism * untreaed hyperprolactinemia * study drug hypersensitivity * previous ohss * unilateral ovariectomy * genital malformation * bmi\>40

Keywords: fertilization in vitro antagonist protocol antral follicle count anti-mullerian hormone reproductive techniques, assisted